People with Crohn’s disease are typically treated with powerful anti-inflammatory medications that act throughout their body, not just in their digestive tract, creating the potential…
The Temple Lupus Program, part of the Lupus Clinical Investigators Network (LuCIN), is an academic-based clinical trials network consisting of some of the most prestigious…
Eli Lilly and Co inked a deal to gain worldwide, exclusive licensing rights to the autoimmune and inflammatory disease treatment candidate of Rigel Pharmaceuticals Inc.…
NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of…
TG Therapeutics announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab compared to Aubagio (teriflunomide) in…
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced…
The National Institutes of Health has awarded the Oklahoma Medical Research Foundation $3.7 million to continue research on Sjögren’s syndrome, an autoimmune disease. OMRF scientist…
Indiana University (IU) School of Medicine and Eli Lilly have come together to transform how university research and pharmaceutical companies do business. Why? Because at…
Hansa Biopharma reported data from an investigator-initiated phase 2 trial that evaluated safety, tolerability and efficacy of imlifidase in 15 patients with severe anti-GBM antibody…
Why would a new immunotherapy approach be cause for researchers to reconsider Type 1 diabetes and its treatment? Perhaps a novel modified synthetic peptide-based technology…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
